Celgene shares tumbled early Thursday after the drugmaker said it's withdrawing its submission in Europe for a new indication for its drug Revlimid, which treats the blood cancer multiple myeloma.

looks like the chart came before the news...  one reason I like to look at the weekly charts....

CELG weekly